Recall Sours Abbott’s Infant Formula Results; COVID-19 Test Sales Expected To Cool
Worldwide nutrition sales, adult as well as infant products, during Q1 dropped reported 7% to $1.89bn. US sales were $59m, well below $288m in prior-year period.
You may also be interested in...
Decree imposes steps Abbott must complete before it can begin preparing to restart production, including hiring independent consultant to determine whether facility is compliant with FDA manufacturing and labeling regulations.
House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.
With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.